Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…Abstract Number: 888 • 2014 ACR/ARHP Annual Meeting
Annual Medical Care Expenditures Among US Adults with Gout, 2005 – 2011
Background/Purpose: Costs associated with gout are of growing interest due to its increasing prevalence, but quantifying those costs has been hampered by its co-occurrence with…Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…Abstract Number: 1993 • 2013 ACR/ARHP Annual Meeting
Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study
Background/Purpose: To examine geographic variations of gout prevalence, incidence and management in the United Kingdom. Methods: We used the Clinical Practice Research Data-link (CPRD) to…Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…Abstract Number: 212 • 2013 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change
Background/Purpose: Dual-energy computed tomography (DECT) is an advanced imaging method with potential for monitoring urate deposition in patients with gout. The aim of this prospective…Abstract Number: 1996 • 2013 ACR/ARHP Annual Meeting
Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Background/Purpose: Due to limited/no data for race/ethnicity, our objective was to assess whether HRQOL functional ability and health care utilization in gout patients differs by…Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…Abstract Number: 213 • 2013 ACR/ARHP Annual Meeting
Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography
Background/Purpose: Digital tomosynthesis is a recently developed imaging method in which multiple projected images obtained at different angles are collected with a digital detector. These…Abstract Number: 2001 • 2013 ACR/ARHP Annual Meeting
Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients
Background/Purpose: gout is well known to be associated with comorbid conditions; the Kaiser Permanente Pyramid (KPP) identify high risk people (two higher strata) in the…Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…Abstract Number: 180 • 2013 ACR/ARHP Annual Meeting
Familial Aggregation Of Female Premenopausal Gout –Monogenic, Polygenic Or Clinical Coincidence?
Background/Purpose: Primary gout is a multifactorial disease, in which genetic background and environmental factors interact with each other. Genetic predisposition is particularly prominent in those…Abstract Number: 2007 • 2013 ACR/ARHP Annual Meeting
Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes
Background/Purpose: Gout flares are the most common manifestation of gout. Gout flares are not well documented by diagnosis codes and are not adequately captured when…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 49
- Next Page »
